LeMaitre Vascular
LMAT
79.31
+0.26
+0.33%
LeMaitre Vascular
US · LMAT
#2839 by market cap
Listed 1970
79.31
+0.26
+0.33%
Live - 5344 symbols - heartbeat 288s ago
· 2026-10-08 07:00
Pre-market
78.93
-0.48%
After-hours
79.31
0.00%
- Market cap
- 1.81B
- P/E (TTM)i
- 27.73
- P/Bi
- 4.32
- EPSi
- 2.52
- Div yieldi
- 1.13%
- 52W posi
- 3%
Reader sentiment
Are you bullish or bearish on LMAT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.93, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +13.53% YoY
Margins
- Gross margin
- 71.53%
- Operating margin
- 27.21%
- Net margin
- 23.13%
Key ratios & quality
- Enterprise valuei
- 1.63B
- PEG ratioi
- 0.68
- Altman Z-Scorei
- 6.93
PEG uses trailing P/E against the 3-year net income growth rate (40.91%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 105.57M | 117.23M | 129.37M | 154.42M | 161.65M | 193.48M | 219.86M | 249.60M |
| Gross profit | 73.94M | 79.85M | 84.62M | 101.38M | 104.90M | 127.05M | 150.90M | 178.54M |
| Selling & admin expenses | 45.01M | 49.39M | 46.20M | 53.16M | 61.67M | 72.89M | 83.00M | 96.49M |
| Research & development | 8.20M | 9.28M | 10.10M | 11.80M | 13.29M | 16.97M | 15.65M | 14.14M |
| Operating profit | 20.74M | 21.18M | 28.32M | 36.43M | 29.94M | 37.20M | 52.26M | 67.91M |
| Pretax profit | 28.44M | 21.68M | 27.36M | 34.29M | 27.49M | 39.48M | 56.88M | 75.18M |
| Tax | 5.50M | 3.75M | 6.14M | 7.38M | 6.85M | 9.37M | 12.84M | 17.45M |
| Net profit | 22.94M | 17.93M | 21.22M | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
| Diluted EPS | 1.13 | 0.88 | 1.04 | 1.25 | 0.93 | 1.34 | 1.93 | 2.52 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 59.87M | 64.23M | 61.05M | 64.45M | 66.55M | 70.38M |
| Gross profit | 41.42M | 44.97M | 45.96M | 46.19M | 48.40M | 50.76M |
| Selling & admin expenses | 24.70M | 25.29M | 22.67M | 23.83M | 26.56M | 25.52M |
| Research & development | 4.10M | 3.54M | 2.97M | 3.53M | 4.06M | 4.85M |
| Operating profit | 12.63M | 16.14M | 20.31M | 18.83M | 17.78M | 20.40M |
| Pretax profit | 14.24M | 18.07M | 22.57M | 20.30M | 19.67M | 22.19M |
| Tax | 3.23M | 4.29M | 5.21M | 4.72M | 3.99M | 5.14M |
| Net profit | 11.01M | 13.78M | 17.36M | 15.58M | 15.68M | 17.05M |
| Basic EPS | 0 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.48 | 0.60 | 0.75 | 0.68 | 0.68 | 0.74 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 94.02M | 92.09M | 94.26M | 139.88M | 161.73M | 194.60M | 402.19M | 468.23M |
| Cash & ST investments | 47.99M | 32.68M | 26.98M | 69.96M | 82.69M | 105.07M | 299.72M | 359.12M |
| Inventory | 25.57M | 34.63M | 39.17M | 40.65M | 45.28M | 52.33M | 55.94M | 58.25M |
| Total assets | 153.09M | 188.34M | 252.81M | 292.80M | 310.48M | 346.78M | 551.82M | 615.69M |
| Total current liabilities | 19.76M | 20.85M | 25.15M | 21.81M | 25.33M | 29.88M | 30.61M | 36.32M |
| Short-term debt | -- | 1.76M | 4.45M | 1.87M | 1.89M | 2.47M | 2.68M | 2.94M |
| Long-term debt | -- | -- | 35.53M | -- | -- | -- | 167.77M | 168.65M |
| Total liabilities | 22,853,000.00 | 40,200,000.00 | 80,238,000.00 | 38,651,000.00 | 42,275,000.00 | 48,878,000.00 | 214,527,000.00 | 222,174,000.00 |
| Total equity | 130.24M | 148.14M | 172.57M | 254.15M | 268.20M | 297.90M | 337.29M | 393.52M |
| Retained earnings | 45.83M | 57.03M | 70.55M | 88.13M | 97.77M | 115.43M | 145.09M | 184.72M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 408.11M | 430.13M | 452.03M | 468.23M | 477.82M | 488.30M |
| Cash & ST investments | 302.55M | 319.49M | 343.06M | 359.12M | 367.23M | 376.24M |
| Inventory | 55.97M | 57.46M | 58.93M | 58.25M | 57.77M | 57.94M |
| Total assets | 556.01M | 577.59M | 598.07M | 615.69M | 629.53M | 640.55M |
| Total current liabilities | 24.75M | 30.82M | 33.29M | 36.32M | 33.37M | 29.94M |
| Short-term debt | 2.64M | 2.83M | 2.79M | 2.94M | 3.45M | 3.44M |
| Long-term debt | 167.98M | 168.21M | 168.42M | 168.65M | 168.87M | 169.09M |
| Total liabilities | 208,434,000.00 | 214,905,000.00 | 219,146,000.00 | 222,174,000.00 | 222,904,000.00 | 220,207,000.00 |
| Total equity | 347.57M | 362.69M | 378.92M | 393.52M | 406.62M | 420.34M |
| Retained earnings | 151.58M | 160.84M | 173.67M | 184.72M | 194.68M | 206.02M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 19.51M | 14.18M | 34.80M | 35.10M | 25.38M | 36.75M | 44.12M | 81.25M |
| Depreciation & amortization | 4.32M | 5.42M | 8.40M | 11.07M | 9.43M | 9.52M | 9.61M | 10.42M |
| Free cash flow | 16.45M | 10.42M | 31.82M | 30.22M | 22.15M | 29.49M | 37.16M | 74.47M |
| Dividends paid | -5.45M | -6.74M | -7.70M | -9.34M | -10.99M | -12.45M | -14.38M | -18.11M |
| Stock buybacks / issuance | 2.23M | 4.17M | 5.40M | 63.24M | 3.47M | -- | -- | -- |
| Ending cash balance | 26.32M | 11.79M | 26.76M | 13.86M | 19.13M | 24.27M | 25.61M | 28.24M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 9.04M | 20.29M | 28.76M | 23.16M | 15.09M | 15.97M |
| Depreciation & amortization | 2.55M | 2.65M | 2.61M | 2.61M | 2.62M | 2.66M |
| Free cash flow | 7.66M | 18.95M | 26.48M | 21.38M | 12.31M | 13.65M |
| Dividends paid | -4.52M | -4.52M | -4.54M | -4.54M | -5.71M | -5.72M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 25.34M | 27.18M | 25.49M | 28.24M | 26.85M | 26.63M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 19.12 | 12.88 | 13.23 | 12.61 | 7.90 | 10.64 | 13.87 | 15.80 |
| ROA %i | 16.42 | 10.51 | 9.62 | 9.86 | 6.84 | 9.16 | 9.80 | 9.89 |
| ROIC %i | 18.70 | 11.21 | 11.29 | 11.46 | 7.17 | 9.22 | 9.61 | 11.20 |
| 5-year avg ROE %i | 13.25 | 14.57 | 15.09 | 15.05 | 13.15 | 11.45 | 11.65 | 12.16 |
| EBIT margin %i | 26.95 | 18.49 | 22.16 | 23.64 | 17.01 | 20.40 | 25.96 | 32.20 |
| FCF / sales %i | 15.58 | 8.89 | 24.60 | 19.57 | 13.70 | 15.24 | 16.90 | 29.83 |
| Current ratioi | 4.76 | 4.42 | 3.75 | 6.41 | 6.39 | 6.51 | 13.14 | 12.89 |
| Quick ratioi | 3.22 | 2.36 | 1.85 | 4.11 | 4.13 | 4.36 | 10.77 | 10.81 |
| Debt / assetsi | 0.00 | 8.34 | 21.67 | 5.44 | 5.35 | 5.51 | 33.65 | 30.14 |
| LT debt / equityi | -- | 9.42 | 29.16 | 5.53 | 5.48 | 5.58 | 54.26 | 46.41 |
| Interest coveragei | 14,223.00 | -- | 21.88 | 16.45 | -- | -- | 278.44 | 15.50 |
| Revenue CAGR (3Y) %i | 10.45 | 9.56 | 8.65 | 13.52 | 11.30 | 14.36 | 12.50 | 15.58 |
| Net income CAGR (3Y) %i | 43.54 | 19.20 | 7.30 | 5.46 | 4.79 | 12.37 | 17.85 | 40.91 |
| FCF CAGR (3Y) %i | 21.61 | -9.50 | 24.59 | 22.47 | 28.58 | -2.51 | 7.14 | 49.81 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 13.77 | 13.81 | 15.02 | 15.80 | 16.55 | 16.77 |
| ROA %i | 9.93 | 10.02 | 10.94 | 9.89 | 10.53 | 10.78 |
| ROIC %i | 9.53 | 9.60 | 10.44 | 11.20 | 11.76 | 12.03 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 26.44 | 27.14 | 30.31 | 32.20 | 33.48 | 34.27 |
| FCF / sales %i | 18.17 | 22.30 | 27.50 | 29.83 | 30.87 | 28.13 |
| Current ratioi | 16.49 | 13.96 | 13.58 | 12.89 | 14.32 | 16.31 |
| Quick ratioi | 13.65 | 11.55 | 11.28 | 10.81 | 12.08 | 13.76 |
| Debt / assetsi | 33.34 | 32.18 | 31.04 | 30.14 | 30.15 | 29.70 |
| LT debt / equityi | 52.57 | 50.47 | 48.25 | 46.41 | 45.83 | 44.44 |
| Interest coveragei | 40.01 | 22.79 | 17.84 | 15.50 | 16.52 | 17.30 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development, manufacturing, and marketing of medical devices and implants, as well as the processing100.00%
Quote time 2026-10-08 07:00:15 · For reference only, not investment advice and not tailored to your situation.